Detection of Primary Melanoma in Individuals at Extreme High Risk: a Prospective 5-year Follow-up Study
Overview
Authors
Affiliations
Importance: The clinical phenotype and certain predisposing genetic mutations that confer increased melanoma risk are established; however, no consensus exists regarding optimal screening for such individuals. Early identification remains the most important intervention in reducing melanoma mortality.
Objective: To evaluate the impact of full-body examinations every 6 months supported by dermoscopy and total-body photography (TBP) on all patients and sequential digital dermoscopy imaging (SDDI), when indicated, on detecting primary melanoma in an extreme-risk population.
Design, Setting, And Participants: Prospective observational study from February 2006 to February 2011, with patients recruited from Sydney Melanoma Diagnostic Centre and Melanoma Institute Australia who had a history of invasive melanoma and dysplastic nevus syndrome, history of invasive melanoma and at least 3 first-degree or second-degree relatives with prior melanoma, history of at least 2 primary invasive melanomas, or a CDKN2A or CDK4 gene mutation.
Exposures: Six-month full-body examination compared with TBP. For equivocal lesions, SDDI short term (approximately 3 months) or long term (≥6 months), following established criteria, was performed. Atypical lesions were excised.
Main Outcomes And Measures: New primary melanoma numbers, characteristics, and cumulative incidence in each patient subgroup; effect of diagnostic aids on new melanoma identification.
Results: In 311 patients with a median (interquartile range [IQR]) follow-up of 3.5 (2.4-4.2) years, 75 primary melanomas were detected, 14 at baseline visit. Median (IQR) Breslow thickness of postbaseline incident melanomas was in situ (in situ to 0.60 mm). Thirty-eight percent were detected using TBP and 39% with SDDI. Five melanomas were greater than 1 mm Breslow thickness, 3 of which were histologically desmoplastic; the other 2 had nodular components. The benign to malignant excision ratio was 1.6:1 for all lesions excised and 4.4:1 for melanocytic lesions. Cumulative risk of developing a novel primary melanoma was 12.7% by year 2, with new primary melanoma incidence during the final 3 years of follow-up half of that observed during the first 2 years (incidence density ratio, 0.43 [95% CI, 0.25-0.74]; P = .002).
Conclusions And Relevance: Monitoring patients at extreme risk with TBP and SDDI assisted with early diagnosis of primary melanoma. Hypervigilance for difficult-to-detect thick melanoma subtypes is crucial.
Hobelsberger S, Steininger J, Meier F, Beissert S, Gellrich F Dermatology. 2024; 240(5-6):803-813.
PMID: 39378859 PMC: 11651331. DOI: 10.1159/000541894.
Jurakic Toncic R, Vasari L, Stulhofer Buzina D, Ledic Drvar D, Petkovic M, Ceovic R Life (Basel). 2024; 14(9).
PMID: 39337982 PMC: 11432978. DOI: 10.3390/life14091200.
Chan S, Guitera P, Ferguson P, El Sharouni M, Teh R, Scolyer R J Eur Acad Dermatol Venereol. 2024; 39(3):594-603.
PMID: 38925576 PMC: 11851254. DOI: 10.1111/jdv.20188.
Primiero C, Betz-Stablein B, Ascott N, DAlessandro B, Gaborit S, Fricker P Front Med (Lausanne). 2024; 11:1380984.
PMID: 38654834 PMC: 11035726. DOI: 10.3389/fmed.2024.1380984.
Overdiagnosis in Melanoma Screening: Is It a Real Problem?.
Betz-Stablein B, Soyer H Dermatol Pract Concept. 2023; 13(4).
PMID: 37992381 PMC: 10656178. DOI: 10.5826/dpc.1304a247.